The impact of improved treatment strategies on overall survival in glioblastoma patients
Background The introduction of ALA-Fluorescence-guided surgery (FGS) followed by concomitant radiochemotherapy according to the Stupp-protocol is representative of the major changes in glioblastoma therapy in the past years. We were interested in the impact of this new first-line treatment on the ov...
Gespeichert in:
| Veröffentlicht in: | Acta neurochirurgica 2013-06, Vol.155 (6), p.959-963 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 963 |
|---|---|
| container_issue | 6 |
| container_start_page | 959 |
| container_title | Acta neurochirurgica |
| container_volume | 155 |
| creator | Slotty, P. J. Siantidis, B. Beez, T. Steiger, H. J. Sabel, M. |
| description | Background
The introduction of ALA-Fluorescence-guided surgery (FGS) followed by concomitant radiochemotherapy according to the Stupp-protocol is representative of the major changes in glioblastoma therapy in the past years. We were interested in the impact of this new first-line treatment on the overall survival of patients suffering from newly diagnosed primary glioblastoma in a retrospective single-centre study.
Method
For this retrospective analysis, data was derived from a prospective single-centre database. Patients were divided into three treatment groups: A (FGS−/radiochemotherapy−), B (FGS−/radiochemotherapy+) and C (FGS+/radiochemotherapy+). Further stratification was applied regarding MGMT-methylation status and degree of resection. Statistical analysis was performed to determine factors (treatment regime, age, gender, performance status, MGMT promoter methylation status) significantly influencing overall survival (OAS).
Results
Two hundred and fifty-three patients suffering from primary glioblastoma treated by cytoreductive surgery between 2002 and 2009 were included in this survey. Median OAS differed significantly between the treatment groups (A = 8.8, B = 16.6, C = 20.1,
p
|
| doi_str_mv | 10.1007/s00701-013-1693-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1356935385</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2977834981</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-b0dd7a067ddbeacf70869277f614c016fcbf61d94bfceea817ab5a341803f4643</originalsourceid><addsrcrecordid>eNqNkUtLAzEUhYMotlZ_gBsJuHEzmkwyycxSii8ouKngbshkkpoyj5pkCv5779AqIghubk6437l5HITOKbmmhMibAIXQhFCWUFFAOUBTUvA0gUIOQRPoilTkE3QSwhp2qeTsGE1SluV5KsUUvS7fDHbtRumIezsq329NjaM3KramizhEr6JZORNw32FoetU0OAx-67aqwa7Dq8b1VaNC7FuFNyo6sIVTdGRVE8zZfp2hl_u75fwxWTw_PM1vF4nmksakInUtFRGyriujtJUkF0UqpRWUa0KF1RXIuuCV1caonEpVZYpxmhNmueBshq52c-Hi74MJsWxd0KZpVGf6IZSUZfA1Gcuz_6CMcMbyAtDLX-i6H3wHDxkpzikT2UjRHaV9H4I3ttx41yr_UVJSjgmVu4RKSKgcEwLzDF3sJw9Va-pvx1ckAKQ7IECrWxn_4-g_p34CVT-byg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1354413659</pqid></control><display><type>article</type><title>The impact of improved treatment strategies on overall survival in glioblastoma patients</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Slotty, P. J. ; Siantidis, B. ; Beez, T. ; Steiger, H. J. ; Sabel, M.</creator><creatorcontrib>Slotty, P. J. ; Siantidis, B. ; Beez, T. ; Steiger, H. J. ; Sabel, M.</creatorcontrib><description>Background
The introduction of ALA-Fluorescence-guided surgery (FGS) followed by concomitant radiochemotherapy according to the Stupp-protocol is representative of the major changes in glioblastoma therapy in the past years. We were interested in the impact of this new first-line treatment on the overall survival of patients suffering from newly diagnosed primary glioblastoma in a retrospective single-centre study.
Method
For this retrospective analysis, data was derived from a prospective single-centre database. Patients were divided into three treatment groups: A (FGS−/radiochemotherapy−), B (FGS−/radiochemotherapy+) and C (FGS+/radiochemotherapy+). Further stratification was applied regarding MGMT-methylation status and degree of resection. Statistical analysis was performed to determine factors (treatment regime, age, gender, performance status, MGMT promoter methylation status) significantly influencing overall survival (OAS).
Results
Two hundred and fifty-three patients suffering from primary glioblastoma treated by cytoreductive surgery between 2002 and 2009 were included in this survey. Median OAS differed significantly between the treatment groups (A = 8.8, B = 16.6, C = 20.1,
p
< 0.01). Resection data was available in all 253 patients. The usage of FGS highly significantly correlated with a complete resection (
p
< 0.01). Complete resection was positively correlated with an increase in OAS (complete 20.3 months vs. incomplete 9.3 months,
p
< 0.01).
Conclusions
FGS and radiochemotherapy according to the Stupp protocol have induced an impressive improvement in overall survival in glioblastoma patients. This effect is not limited to clinical trials, but is reproducible in daily routine.</description><identifier>ISSN: 0001-6268</identifier><identifier>EISSN: 0942-0940</identifier><identifier>DOI: 10.1007/s00701-013-1693-1</identifier><identifier>PMID: 23588276</identifier><language>eng</language><publisher>Vienna: Springer Vienna</publisher><subject>Adolescent ; Adult ; Aged ; Brain Neoplasms - mortality ; Brain Neoplasms - therapy ; Chemoradiotherapy - methods ; Clinical Article - Brain Tumors ; Disease-Free Survival ; Glioblastoma - mortality ; Glioblastoma - therapy ; Humans ; Interventional Radiology ; Medicine ; Medicine & Public Health ; Middle Aged ; Minimally Invasive Surgery ; Neurology ; Neuroradiology ; Neurosurgery ; Neurosurgical Procedures - methods ; Retrospective Studies ; Surgical Orthopedics ; Treatment Outcome ; Young Adult</subject><ispartof>Acta neurochirurgica, 2013-06, Vol.155 (6), p.959-963</ispartof><rights>Springer-Verlag Wien 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-b0dd7a067ddbeacf70869277f614c016fcbf61d94bfceea817ab5a341803f4643</citedby><cites>FETCH-LOGICAL-c471t-b0dd7a067ddbeacf70869277f614c016fcbf61d94bfceea817ab5a341803f4643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00701-013-1693-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00701-013-1693-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23588276$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Slotty, P. J.</creatorcontrib><creatorcontrib>Siantidis, B.</creatorcontrib><creatorcontrib>Beez, T.</creatorcontrib><creatorcontrib>Steiger, H. J.</creatorcontrib><creatorcontrib>Sabel, M.</creatorcontrib><title>The impact of improved treatment strategies on overall survival in glioblastoma patients</title><title>Acta neurochirurgica</title><addtitle>Acta Neurochir</addtitle><addtitle>Acta Neurochir (Wien)</addtitle><description>Background
The introduction of ALA-Fluorescence-guided surgery (FGS) followed by concomitant radiochemotherapy according to the Stupp-protocol is representative of the major changes in glioblastoma therapy in the past years. We were interested in the impact of this new first-line treatment on the overall survival of patients suffering from newly diagnosed primary glioblastoma in a retrospective single-centre study.
Method
For this retrospective analysis, data was derived from a prospective single-centre database. Patients were divided into three treatment groups: A (FGS−/radiochemotherapy−), B (FGS−/radiochemotherapy+) and C (FGS+/radiochemotherapy+). Further stratification was applied regarding MGMT-methylation status and degree of resection. Statistical analysis was performed to determine factors (treatment regime, age, gender, performance status, MGMT promoter methylation status) significantly influencing overall survival (OAS).
Results
Two hundred and fifty-three patients suffering from primary glioblastoma treated by cytoreductive surgery between 2002 and 2009 were included in this survey. Median OAS differed significantly between the treatment groups (A = 8.8, B = 16.6, C = 20.1,
p
< 0.01). Resection data was available in all 253 patients. The usage of FGS highly significantly correlated with a complete resection (
p
< 0.01). Complete resection was positively correlated with an increase in OAS (complete 20.3 months vs. incomplete 9.3 months,
p
< 0.01).
Conclusions
FGS and radiochemotherapy according to the Stupp protocol have induced an impressive improvement in overall survival in glioblastoma patients. This effect is not limited to clinical trials, but is reproducible in daily routine.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - therapy</subject><subject>Chemoradiotherapy - methods</subject><subject>Clinical Article - Brain Tumors</subject><subject>Disease-Free Survival</subject><subject>Glioblastoma - mortality</subject><subject>Glioblastoma - therapy</subject><subject>Humans</subject><subject>Interventional Radiology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Minimally Invasive Surgery</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosurgery</subject><subject>Neurosurgical Procedures - methods</subject><subject>Retrospective Studies</subject><subject>Surgical Orthopedics</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0001-6268</issn><issn>0942-0940</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkUtLAzEUhYMotlZ_gBsJuHEzmkwyycxSii8ouKngbshkkpoyj5pkCv5779AqIghubk6437l5HITOKbmmhMibAIXQhFCWUFFAOUBTUvA0gUIOQRPoilTkE3QSwhp2qeTsGE1SluV5KsUUvS7fDHbtRumIezsq329NjaM3KramizhEr6JZORNw32FoetU0OAx-67aqwa7Dq8b1VaNC7FuFNyo6sIVTdGRVE8zZfp2hl_u75fwxWTw_PM1vF4nmksakInUtFRGyriujtJUkF0UqpRWUa0KF1RXIuuCV1caonEpVZYpxmhNmueBshq52c-Hi74MJsWxd0KZpVGf6IZSUZfA1Gcuz_6CMcMbyAtDLX-i6H3wHDxkpzikT2UjRHaV9H4I3ttx41yr_UVJSjgmVu4RKSKgcEwLzDF3sJw9Va-pvx1ckAKQ7IECrWxn_4-g_p34CVT-byg</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Slotty, P. J.</creator><creator>Siantidis, B.</creator><creator>Beez, T.</creator><creator>Steiger, H. J.</creator><creator>Sabel, M.</creator><general>Springer Vienna</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20130601</creationdate><title>The impact of improved treatment strategies on overall survival in glioblastoma patients</title><author>Slotty, P. J. ; Siantidis, B. ; Beez, T. ; Steiger, H. J. ; Sabel, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-b0dd7a067ddbeacf70869277f614c016fcbf61d94bfceea817ab5a341803f4643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - therapy</topic><topic>Chemoradiotherapy - methods</topic><topic>Clinical Article - Brain Tumors</topic><topic>Disease-Free Survival</topic><topic>Glioblastoma - mortality</topic><topic>Glioblastoma - therapy</topic><topic>Humans</topic><topic>Interventional Radiology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Minimally Invasive Surgery</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosurgery</topic><topic>Neurosurgical Procedures - methods</topic><topic>Retrospective Studies</topic><topic>Surgical Orthopedics</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Slotty, P. J.</creatorcontrib><creatorcontrib>Siantidis, B.</creatorcontrib><creatorcontrib>Beez, T.</creatorcontrib><creatorcontrib>Steiger, H. J.</creatorcontrib><creatorcontrib>Sabel, M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Acta neurochirurgica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Slotty, P. J.</au><au>Siantidis, B.</au><au>Beez, T.</au><au>Steiger, H. J.</au><au>Sabel, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of improved treatment strategies on overall survival in glioblastoma patients</atitle><jtitle>Acta neurochirurgica</jtitle><stitle>Acta Neurochir</stitle><addtitle>Acta Neurochir (Wien)</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>155</volume><issue>6</issue><spage>959</spage><epage>963</epage><pages>959-963</pages><issn>0001-6268</issn><eissn>0942-0940</eissn><abstract>Background
The introduction of ALA-Fluorescence-guided surgery (FGS) followed by concomitant radiochemotherapy according to the Stupp-protocol is representative of the major changes in glioblastoma therapy in the past years. We were interested in the impact of this new first-line treatment on the overall survival of patients suffering from newly diagnosed primary glioblastoma in a retrospective single-centre study.
Method
For this retrospective analysis, data was derived from a prospective single-centre database. Patients were divided into three treatment groups: A (FGS−/radiochemotherapy−), B (FGS−/radiochemotherapy+) and C (FGS+/radiochemotherapy+). Further stratification was applied regarding MGMT-methylation status and degree of resection. Statistical analysis was performed to determine factors (treatment regime, age, gender, performance status, MGMT promoter methylation status) significantly influencing overall survival (OAS).
Results
Two hundred and fifty-three patients suffering from primary glioblastoma treated by cytoreductive surgery between 2002 and 2009 were included in this survey. Median OAS differed significantly between the treatment groups (A = 8.8, B = 16.6, C = 20.1,
p
< 0.01). Resection data was available in all 253 patients. The usage of FGS highly significantly correlated with a complete resection (
p
< 0.01). Complete resection was positively correlated with an increase in OAS (complete 20.3 months vs. incomplete 9.3 months,
p
< 0.01).
Conclusions
FGS and radiochemotherapy according to the Stupp protocol have induced an impressive improvement in overall survival in glioblastoma patients. This effect is not limited to clinical trials, but is reproducible in daily routine.</abstract><cop>Vienna</cop><pub>Springer Vienna</pub><pmid>23588276</pmid><doi>10.1007/s00701-013-1693-1</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-6268 |
| ispartof | Acta neurochirurgica, 2013-06, Vol.155 (6), p.959-963 |
| issn | 0001-6268 0942-0940 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1356935385 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Adult Aged Brain Neoplasms - mortality Brain Neoplasms - therapy Chemoradiotherapy - methods Clinical Article - Brain Tumors Disease-Free Survival Glioblastoma - mortality Glioblastoma - therapy Humans Interventional Radiology Medicine Medicine & Public Health Middle Aged Minimally Invasive Surgery Neurology Neuroradiology Neurosurgery Neurosurgical Procedures - methods Retrospective Studies Surgical Orthopedics Treatment Outcome Young Adult |
| title | The impact of improved treatment strategies on overall survival in glioblastoma patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T12%3A46%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20improved%20treatment%20strategies%20on%20overall%20survival%20in%20glioblastoma%20patients&rft.jtitle=Acta%20neurochirurgica&rft.au=Slotty,%20P.%20J.&rft.date=2013-06-01&rft.volume=155&rft.issue=6&rft.spage=959&rft.epage=963&rft.pages=959-963&rft.issn=0001-6268&rft.eissn=0942-0940&rft_id=info:doi/10.1007/s00701-013-1693-1&rft_dat=%3Cproquest_cross%3E2977834981%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1354413659&rft_id=info:pmid/23588276&rfr_iscdi=true |